我是 LongbridgeAI，我可以总结文章信息。人工智能生物技术悖论：Moderna 与默克的第三阶段黑色素瘤数据为人工智能辅助的个性化癌症疫苗提供了另一个验证点。但投资者冒着将其视为软件交易的风险，而生物学并不是软件。人工智能可以在几秒钟内生成数千种生物设计，但实际合成、测试和验证这些设计仍然可能需要数月时间
The AI Biotech Paradox
Moderna’s Phase 3 melanoma data with Merck provides another validation point for AI-assisted personalized cancer vaccines. But investors risk treating this like a software trade, and biology is not software.
AI can generate thousands of biological designs in seconds, but physically synthesizing, testing and validating them can still take months.